|
Baseline
|
Follow-up (12 months)
| | | |
---|
Outcome (clinician behaviour)
|
Intervention
|
Control
|
Intervention
|
Control
|
Effect size (95%CI)
|
p
|
ICC
|
---|
Prescribed additional therapy for glycemic control1
|
29%
|
31%
|
37%
|
35%
|
IRR 1.18 (0.95 to 1.48)
|
0.13
|
–
|
(95%CI 21–36%)
|
(95%CI 22–41%)
|
(95%CI 31–43%)
|
(95%CI 29–41%)
|
Prescribed additional therapy for blood pressure2
|
45%
|
45%
|
53%
|
50%
|
IRR 1.05 (0.96 to 1.16)
|
0.29
|
–
|
(95%CI 37–52%)
|
(95%CI 42–47%)
|
(95%CI 47–59%)
|
(95%CI 46–53%)
|
Examined circulation and sensation in feet3
|
75%
|
74%
|
78%
|
79%
|
OR 0.84 (0.75 to 0.94)
|
< 0.01
|
0.03
|
- Note: Percentages based on uncorrected means. Effect sizes adjusted for baseline and practice size. ICC not calculated for prescribing as unit of analysis was the practice level
- IRR incidence rate ratio, OR odds ratio, ICC intracluster correlation
- 1Numerator: number of patients prescribed insulin for the first time. Denominator: Number of patients with type 2 diabetes in each practice with an HbA1c measure exceeding 58 mmol/mol (7.5%) at least once in the 12 months post-intervention who were also on three or more oral hypoglycemic drugs
- 2Numerator: number of patients prescribed an additional antihypertensive drug or had tablet size changed. Denominator: patients with type 2 diabetes in each practice with at least one blood pressure measure above 140/80 mmHg, excluding those with a subsequent follow-up measure below blood pressure threshold
- 3Numerator: patients with recorded examination of sensation and circulation in each foot. Denominator: all patients meeting inclusion criteria